OOIR: Observatory of International Research

Papers

(The TQCC of Cancer and Metastasis Reviews is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	285
Obesity and cancer	154
The functions and modifications of tRNA-derived small RNAs in cancer biology	130
Clonal tracking in cancer and metastasis	123
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities	97
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective	96
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms	85
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression	77
Regulation of dormancy during tumor dissemination: the role of the ECM	61
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	60
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor	59
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	58
CAR T-cell therapy to treat multiple myeloma: current state and future directions	56
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer	55
Targeting lipid metabolism in cancer: neuroblastoma	54
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives	52
p73 isoforms meet evolution of metastasis	46
Cell-cell interactions mediating primary and metastatic breast cancer dormancy	45
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond	43
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review	43
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	41
Biography—Mathieu Boissan, Pharm.D., Ph.D	38
Preface	37
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	37
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance	35

Neuropeptide Y in cancer—biological functions and potential clinical implications	33
Biographies	33
The role of cancer cell bioenergetics in dormancy and drug resistance	32
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	32
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	32
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance	31
Short-chain fatty acids in cancer pathogenesis	30
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development	29
Tumor necrosis factor superfamily signaling: life and death in cancer	29
Clusterin: a marker and mediator of chemoresistance in colorectal cancer	29
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy	29
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	29
Clinical interventions to break the obesity and cancer link: a narrative review	29
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy	28
The emerging roles of histone demethylases in cancers	28
Vaping and tumor metastasis: current insights and progress	28
Functional and clinical roles of stromal PDGF receptors in tumor biology	28
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions	28
Carcinoma of unknown primary (CUP): an update for histopathologists	28
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy	27
Kenneth V. Honn, Ph.D. (1946–2023)	27
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review	27
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape	26
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	25
OX40/OX40 ligand and its role in precision immune oncology	24
Inflammatory bowel disease and carcinogenesis	24
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	23
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect	23
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective	23
New progress of tuberculosis scar carcinoma	22
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases	22
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting	22
HOXA9 transcription factor is a double-edged sword: from development to cancer progression	21
Biographies	21
Ferroptosis: iron release mechanisms in the bioenergetic process	21